From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

The effective and sensitive monitoring of Minimal Residual Disease or Measurable Residual
Disease (MRD) is a very important aspect in the management of patients affected by …

Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …

Simple Summary There is still a lack of reliable molecular predictors to achieve major
molecular response (MMR, BCR:: ABL1≤ 0.1% IS) within the first year of treatment with …

The standard-of-care treatment for patients with acute myeloid leukemia (AML) is being
challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors …

Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of patients with chronic
myeloid leukemia. Patients who achieve sustained deep molecular response are eligible for …

Introduction Chronic myeloid leukemia (CML) is a chronic disease with treatment-free
remission (TFR) increasingly regarded as a feasible goal of treatment. However, various …

Clinical trials in chronic myeloid leukemia (CML) are usually carried out in specialized
centers whereas primary care for patients (pts) with CML is mainly provided by local …

The experience of a physician at a clinical center is among the critical factors in managing
chronic myeloid leukemia (CML) during its treatment with tyrosine kinase inhibitors (TKIs) …

Precise quantification of the JAK2 V617F mutation using highly sensitive assays is crucial for
diagnosis, treatment process monitoring, and prognostic prediction in myeloproliferative …